Date: 08/12/2021
Category: Corporate Update
August 2021 Update
Ichnos Sciences aims to shift the way the world thinks about innovation in medicine by developing potentially transformative biologic treatments in oncology and autoimmune disease. The company, headquartered in New York City, with discovery and manufacturing at two sites in Switzerland, has approximately 200 employees and strong capabilities in the research and development of new biological entities (NBEs).
To read more, download the full update PDF.
Recent updates
-
August 2023 Update
. Read more
- Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001. Read more
- Ichnos Sciences Welcomes Lida Pacaud, M.D., as New Chief Medical Officer. Read more
-
May 2023 Update . Read more
- Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442. Read more
View Career Opportunities
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
